Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
RGLS Stock Forecast 2026-2027
$8.16
Current Price
$564.95M
Market Cap
Buy 1
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to RGLS Price Targets
-14.2%
To High Target of $7.00
-14.2%
To Median Target of $7.00
-14.2%
To Low Target of $7.00
RGLS Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
+542.5%
1 Year Change
0.0%
Year-to-Date Change
-2.3%
From 52W High of $8.35
+883.1%
From 52W Low of $0.83
📊 TOP ANALYST CALLS
Did RGLS Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Regulus is one of their latest high-conviction picks.
Latest RGLS Stock Price Targets & Analyst Predictions
Based on our analysis of 12 Wall Street analysts, RGLS has a neutral consensus with a median price target of $7.00 (ranging from $7.00 to $7.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $8.16, the median forecast implies a -14.2% downside. This outlook is supported by 1 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Joseph Schwartz at Leerink Partners, projecting a 14.2% downside. Conversely, the most conservative target is provided by Joseph Schwartz at Leerink Partners, suggesting a 14.2% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
RGLS Analyst Ratings
1
Buy
1
Hold
0
Sell
RGLS Price Target Range
Low
$7.00
Average
$7.00
High
$7.00
Current: $8.16
Latest RGLS Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for RGLS.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 1, 2025 | Wells Fargo | Yanan Zhu | Equal-Weight | Downgrade | $9.00 |
| Apr 30, 2025 | Leerink Partners | Joseph Schwartz | Market Perform | Downgrade | $7.00 |
| Apr 30, 2025 | Canaccord Genuity | Whitney Ijem | Hold | Downgrade | $11.00 |
| Apr 30, 2025 | Jones Trading | Catherine Novack | Hold | Downgrade | $7.00 |
| Mar 27, 2025 | Wells Fargo | Yanan Zhu | Overweight | Upgrade | $6.00 |
| Mar 17, 2025 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $28.00 |
| Mar 14, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Feb 26, 2025 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Nov 11, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Oct 30, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Oct 8, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Aug 14, 2024 | Oppenheimer | Andreas Argyrides | Outperform | Reiterates | $7.00 |
| Aug 9, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Jul 16, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $10.00 |
| Jun 25, 2024 | Canaccord Genuity | Whitney Ijem | Buy | Maintains | $28.00 |
| Jun 25, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Maintains | $10.00 |
| May 31, 2024 | Jones Trading | Catherine Novack | Buy | Initiates | $8.00 |
| May 10, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $9.00 |
| May 6, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $9.00 |
| Mar 25, 2024 | HC Wainwright & Co. | Raghuram Selvaraju | Buy | Reiterates | $9.00 |
Regulus Therapeutics Inc. (RGLS) Competitors
The following stocks are similar to Regulus based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Regulus Therapeutics Inc. (RGLS) Financial Data
Regulus Therapeutics Inc. has a market capitalization of $564.95M with a P/E ratio of -10.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -53.8%.
Valuation Metrics
Market Cap
$564.95M
Enterprise Value
$500.99M
P/E Ratio
-10.0x
PEG Ratio
-6.7x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+11.6%
Current Ratio
16.3x
Debt/Equity
2.0x
ROE
-53.8%
ROA
-34.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Regulus Therapeutics Inc. (RGLS) Business Model
About Regulus Therapeutics Inc.
What They Do
Develops innovative microRNA-targeted therapies.
Business Model
Regulus Therapeutics focuses on the discovery and development of medicines that target microRNAs, aiming to treat diseases with unmet medical needs. The company generates revenue through collaborations, partnerships, and potential future product sales stemming from its microRNA-based therapies.
Additional Information
The company emphasizes conditions such as genetic and fibrotic diseases and is involved in clinical trials to advance its therapies. Regulus Therapeutics is positioned as a significant player in the biotechnology sector, contributing to personalized medicine and targeted treatment strategies.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
34
CEO
Mr. Joseph P. Hagan M.B.A.
Country
United States
IPO Year
2012
Website
www.regulusrx.comRegulus Therapeutics Inc. (RGLS) Latest News & Analysis
Latest News
Quick Summary
Novartis has completed its acquisition of Regulus Therapeutics, which is now a wholly owned subsidiary. Regulus shares have ceased trading on Nasdaq.
Why It Matters
Novartis acquiring Regulus Therapeutics eliminates Regulus as a public entity, impacting share liquidity and may affect Novartis's growth strategy in biotech, influencing investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Novartis completed its tender offer to acquire Regulus Therapeutics for $7.00 per share plus a contingent value right for an additional $7.00 upon milestone achievement, which expired June 24, 2025.
Why It Matters
Novartis's tender offer for Regulus shares at $7.00 each, plus potential future payments, signals strategic growth and can impact stock prices and investor sentiment in both companies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Novartis has launched a tender offer to acquire Regulus Therapeutics for $7.00 per share in cash and a contingent value right for an additional $7.00 upon achieving a regulatory milestone.
Why It Matters
Novartis' tender offer for Regulus at $7.00 per share, plus potential milestone payments, indicates strategic growth and could impact stock valuations and investor sentiment in biotech.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Regulus Therapeutics will be acquired by Novartis for $7.00 per share, plus potential additional cash. The deal is valued up to $1.7 billion, expected to close in H2 2025, pending conditions.
Why It Matters
Regulus Therapeutics' acquisition by Novartis at $7.00 per share signals confidence in its pipeline, particularly farabursen for ADPKD, potentially enhancing Novartis’ portfolio and market position.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Regulus Therapeutics Inc. is proposed to be sold to Novartis AG for $7.00 per share in cash, plus a contingent value right for an additional $7.00 per share, pending milestone achievement.
Why It Matters
The investigation into Regulus Therapeutics' sale to Novartis could impact share prices and investor sentiment regarding the deal's viability and potential returns.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Novartis will acquire Regulus Therapeutics for up to $1.7 billion to access its experimental kidney disease drug, enhancing its portfolio in this therapeutic area.
Why It Matters
Novartis's acquisition of Regulus Therapeutics for $1.7 billion highlights its strategy to enhance its pipeline, potentially boosting future revenue through innovative kidney disease treatments.
Source: Reuters
Market Sentiment:
Positive
Frequently Asked Questions About RGLS Stock
What is Regulus Therapeutics Inc.'s (RGLS) stock forecast for 2026?
Based on our analysis of 12 Wall Street analysts, Regulus Therapeutics Inc. (RGLS) has a median price target of $7.00. The highest price target is $7.00 and the lowest is $7.00.
Is RGLS stock a good investment in 2026?
According to current analyst ratings, RGLS has 1 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.16. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for RGLS stock?
Wall Street analysts predict RGLS stock could reach $7.00 in the next 12 months. This represents a -14.2% decrease from the current price of $8.16. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Regulus Therapeutics Inc.'s business model?
Regulus Therapeutics focuses on the discovery and development of medicines that target microRNAs, aiming to treat diseases with unmet medical needs. The company generates revenue through collaborations, partnerships, and potential future product sales stemming from its microRNA-based therapies.
What is the highest forecasted price for RGLS Regulus Therapeutics Inc.?
The highest price target for RGLS is $7.00 from Joseph Schwartz at Leerink Partners, which represents a -14.2% decrease from the current price of $8.16.
What is the lowest forecasted price for RGLS Regulus Therapeutics Inc.?
The lowest price target for RGLS is $7.00 from Joseph Schwartz at Leerink Partners, which represents a -14.2% decrease from the current price of $8.16.
What is the overall RGLS consensus from analysts for Regulus Therapeutics Inc.?
The overall analyst consensus for RGLS is neutral. Out of 12 Wall Street analysts, 1 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $7.00.
How accurate are RGLS stock price projections?
Stock price projections, including those for Regulus Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: January 13, 2026 2:10 PM UTC